SFA Therapeutics, Inc. has announced encouraging results from its Phase 1b clinical trial of SFA-002, an oral drug candidate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback